# Scribe Therapeutics, Inc. — Form D

Scribe Therapeutics, Inc. of ALAMEDA, CA, a company, filed a Form D exempt-offering notice with the SEC on 2021-04-02. The offering totals $100.0M, of which $100.0M was reported sold. Industry: Other Technology.

## Offering

- Filed: 2021-04-02
- Form: D
- Accession: 0001853921-21-000001
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $100.0M
- Amount sold: $100.0M
- Investors: 19
- Date of first sale: 2021-03-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-394477

## Issuer

- Name: Scribe Therapeutics, Inc.
- CIK: 0001853921
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 1150 MARINA VILLAGE PKWY, ALAMEDA, CA, 94501
- Phone: 510-454-0213

## Officers, directors & promoters (5)

| Name | Role | Location |
| --- | --- | --- |
| Behzad Aghazadeh | Director | New York, NY |
| CARL GORDON | Director | SAN DIEGO, CA |
| Benjamin Oakes | Director | Alameda, CA |
| Vijay Pande | Director | Richmond, CA |
| Benjamin Oakes | Executive Officer | Alameda, CA |

## More

- [CIK 1853921 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1853921&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001853921-21-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.